An Investigational Drug for Advanced Melanoma (Skin Cancer) Shrinks Tumors

The investigational drug T-VEC provides a long-lasting response in the treatment of advanced skin cancer.

While more than 3 million people worldwide are diagnosed with skin cancer, this rate is 100 per thousand 16.67 in our country. The number of people developing skin cancer in our country increases every year due to many factors, such as the desire for a tanned complexion and frequent use of tanning beds, unprotected sun exposure, and the rising average age. Any wound on the skin that does not heal or that reopens after appearing to have healed, as well as any spot or mole that is enlarging, should be examined by a doctor and removed with a minor surgical procedure when considered necessary. This method will protect you from possible skin cancer in the future.

Taking biological differences and incidence into consideration, skin cancers are divided into two groups: malignant melanoma and non-melanoma skin cancers. In men, it can be said that the most common non-melanoma skin cancer after lung cancer does not pose a vital risk. Malignant melanoma, which develops on congenital or subsequently appearing moles on the skin, does pose a vital risk if not diagnosed early. Findings such as enlargement, growth, or bleeding on an existing or newly developed spot or mole on the skin, as well as deepening or changes in color in an existing wound, may be signs of malignant melanoma and non-melanoma skin cancers.

The number of studies conducted on skin cancer, whose incidence is increasing year by year, has also grown. In many types of cancer where early diagnosis and effective treatment save lives, every promising approach will benefit patients and make the doctor’s work easier.

Melanoma is highly dangerous because it spreads to other parts of the body more than other types of skin cancer. Therefore, according to data obtained from preliminary studies conducted in recent years in the search for solutions, the drug T-VEC has produced promising results.

T-VEC is a type of immunotherapy that uses a specially designed virus to destroy cancer cells. It is injected directly into the tumor. After becoming locally activated within the tumor, it stimulates the immune system against cancer cells located in other parts of the body.

The results of studies on T-VEC, which is considered potentially beneficial in the search for solutions for advanced skin cancer, were shared with the public recently at the 2013 annual meeting of the American Society of Clinical Oncology. More than 400 patients with stage III or IV melanoma (not amenable to surgical intervention) participated in the study. For 18 months, one group of patients was treated with T-VEC, while the other group received GM-CSF (a drug that stimulates the immune system).

The initial results indicated that the drug produced a long-lasting response to the disease (partial or complete disappearance of the cancer lasted for at least 6 months).

-%16 of patients who used T-VEC and %2 of patients who used GM-CSF had a long-lasting positive response to the disease. In the group that used T-VEC, patients with stage III melanoma were observed to have the most long-lasting response to treatment.

-Overall, %26 of patients who received T-VEC and %6 of patients who received GM-CSF responded to treatment.

-No serious side effects were encountered during treatment.

These results showed that the drug T-VEC is effective in patients with advanced melanoma. Although initial evaluations of T-VEC showed findings indicating that it prolongs survival, a longer observation period is required to reach a conclusion. Nevertheless, the initial results obtained from the study have been recorded as an important step for advanced melanoma skin cancer.